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Abstract
The susceptibilities of 824 Bacteroides fragilis group isolates against nine antibiotics were evaluated in a Europe-wide study involving 13
countries. Species determination, by different methods, was carried out on all but one isolate. Resistance rates were evaluated accord-
ing to species and geographical areas via CLSI and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) break-
points. The present data were compared with those obtained 10 and 20 years ago at a European level. High-level resistance (MIC
‡64 mg/L) to ampicillin was observed in 44.5% of the strains, which is a signiﬁcant increase relative to 20 years ago (16%). Piperacillin/
tazobactam was more active than amoxicillin/clavulanic acid (3.1% and 10.4% resistance, respectively), again with a resistance increase
relative to earlier studies. Dramatic increases in resistance were observed for cefoxitin, clindamycin and moxiﬂoxacin, with rates of
17.2%, 32.4% and 13.6%, respectively. The lowest resistances were found for imipenem, metronidazole and tigecycline (1.2%, <1% and
1.7%). Nonsusceptible strains to imipenem and metronidazole were more resistant to other anti-anaerobic drugs. Differences were
detected between geographical areas, with higher resistance rates for moxiﬂoxacin in Scandinavian countries (21.4%) than in Mediterra-
nean countries (5.4%), whereas, for clindamycin, the resistance rates were higher in Mediterranean (41.8%) and lower in Scandinavian
countries (22.5%). Piperacillin/tazobactam resistance was also higher in Scandinavian countries.
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Introduction
Bacteroides fragilis group strains, the most frequently isolated
anaerobic pathogens causing severe intra-abdominal infec-
tions, postoperative wound infections, and special skin
and soft-tissue infections, together with other aerobic and
anaerobic bacteria, or causative agents of bacteraemias, are
also important constituents of the normal colonic microﬂora.
Monobacterial or mixed infections involving anaerobic bacte-
ria, including B. fragilis group isolates, are usually treated
empirically, based on surveillance reports of the susceptibility
patterns of these pathogens. Changes in the taxonomy of
the Bacteroides genus and an increased number of species
isolated from humans (up to 23, including Parabacteroides
species) were experienced recently [1,2]. During the past
20 years, several studies at a national or hospital level in
different European countries [3–7] and the USA [8,9] fol-
lowed long-term resistance trends for Bacteroides. In the ﬁrst
Europe-wide study on the antibiotic susceptibilities of
B. fragilis group isolates in 1988–1989 [10], 1289 clinical
isolates were collected from 22 laboratories in 15 countries.
In the second study, in 1999–2001 [11], 1284 clinically rele-
vant Bacteroides isolates were collected from 22 laboratories
in 19 countries. Regional variations and increasing resistance
to some traditional antimicrobial agents and some newer
b-lactam antibiotics were reported. Differences in resistance
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rates to some antibiotics were detected among the Bactero-
ides species and between isolates from different clinical
sources. The aims of the third Bacteroides antibiotic suscepti-
bility study, involving 824 isolates from 13 European coun-
tries, were: (i) to evaluate the present situation of the
antibiotic susceptibility of different Bacteroides species, with
resistance rates being compared via the CLSI and the
European Committee on Antimicrobial Susceptibility Testing
(EUCAST) breakpoints where applicable; (ii) to seek species
differences concerning the sources of isolates; (iii) to
seek region-dependent differences in resistance rates;
and (iv) to follow resistance development in this group of
anaerobic bacteria at a European level during the past
20 years.
Materials and Methods
Collection and species determination of bacteria
The 13 countries (Belgium, Croatia, Czech Republic, Finland,
France, Germany, Greece, Hungary, Italy, Spain, Sweden, the
Netherlands and Turkey) included in the present study each
provided three to 103 consecutive, nonduplicate Bacteroides
genus clinical isolates between January 2008 and March 2009.
Because of recent taxonomic changes, some species of Para-
bacteroides genus were also included [2]. The isolates were
sent to the Institute of Clinical Microbiology at the Univer-
sity of Szeged, where species determination was carried out
with the API20 ANA (bioMerieux SA, Marcy-l’Etoile, France)
system or, when needed, traditional identiﬁcation according
to the Wadsworth manual [12]. For a subset of isolates
(277) where no species identiﬁcation was provided by the
isolating laboratory or when there were discrepancies
between the species determinations in the isolating and the
central laboratory, matrix-assisted laser desorption/ionization
time-of-ﬂight mass spectrometry was used for species identi-
ﬁcation [13]. B. fragilis ATCC25285, B. fragilis DSM2151 and
Bacteroides thetaiotaomicron ATCC29741 served as control
strains.
Antimicrobial agents and determination of MICs
MICs of nine antimicrobial agents were determined by the
agar dilution technique as recommended by the CLSI [14].
105 CFU of inocula per spot was placed with a modiﬁed
Steers replicator on the surface of freshly-prepared Brucella
agar (Oxoid, Basingstoke, UK) supplemented with 5% leaked
sheep blood. The plates were incubated for 48 h at 37C in
an anaerobic chamber (Bactron; Sheldon Manufacturing Inc.,
Cornelius, OR, USA). MICs were deﬁned as the lowest con-
centration of antimicrobial agent resulting in marked changes
in the appearance of growth relative to the control plate.
B. fragilis ATCC25285 and B. thetaiotaomicron ATCC29741
served as control strains. The antibiotics tested were: ampi-
cillin, cefoxitin, clindamycin (Sigma-Aldrich Chemie GmbH,
Seelze, Germany), amoxicillin/clavulanic acid (GlaxoSmith-
Kline, Budapest, Hungary), piperacillin/tazobactam, tigecycline
(Wyeth Whitehall GmbH, Vienna, Austria), imipenem/cilasta-
tin (MSD, Budapest, Hungary), metronidazole (Richter
Gedeon Rt, Budapest, Hungary), and moxiﬂoxacin (Bayer
Hungary Kft, Budapest, Hungary). The resistance levels
obtained in the three different studies were generally
compared via the breakpoints recommended by the CLSI,
but available EUCAST breakpoints were also used [14,15].
Results
Bacteria and source of isolation
All strains included in the present study were clinically rele-
vant isolates with deﬁned sources. No strains isolated from
faeces were studied. Some participants had difﬁculties with
respect to collecting the agreed numbers of strains as a
result of a declining interest in routinely culturing anaerobic
bacteria in many European countries. Many isolates were
identiﬁed by the isolating laboratory only at a genus level,
whereas all but one of the 824 Bacteroides/Parabacteroides
isolates were identiﬁed at a species level by different meth-
ods in the central laboratory.
Most isolates were B. fragilis (72.8%) followed by B. thetai-
otaomicron (10.1%), Bacteroides ovatus (5.9%) and Bacteroides
vulgatus (5.1%); a further 11 Bacteroides/Parabacteroides spe-
cies were found in low numbers in different infectious
processes (Table 1). Intra-abdominal infections, wounds, dia-
betic foot infections with ulceration and bloodstream infec-
tions were the most common isolation sources (61.8%).
Besides the frequent species, newly-accepted members of
the Bacteroides genus (Bacteroides nordii [4], Bacteroides
massiliensis [3], Bacteroides salyersae [1] and Parabacteroides
goldsteinii [1]) were also found in clinically relevant materials
(Table 1).
Antibiotic susceptibility
The numbers of isolates, the ranges of MICs, as well as the
MIC50 and MIC90 for each species represented by ten or
more isolates are shown in Table 2. The rates of resistance
were evaluated via the resistance breakpoints of CLSI and
EUCAST in parallel. For ampicillin, piperacillin/tazobactam
and metronidazole, these breakpoints differed; accordingly,
two resistance rates are reported. For amoxicillin/clavulanic
acid, imipenem and clindamycin, the resistance breakpoints
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were the same in the two systems; for cefoxitin, moxiﬂoxa-
cin and tigecycline, no EUCAST breakpoints are available.
Ampicillin
The CLSI and EUCAST resistance breakpoints indicated
resistance in 99% and 98% of the strains, respectively, with
no real differences between the different species. With a
breakpoint of ‡64 mg/L, 44.5% of all isolates proved highly
resistant. This is a major increase compared to the last two
European studies, in which 16% and 27% of the isolates had
a MIC ‡64 mg/L (Table 3).
Amoxicillin/clavulanic acid
Some 8.7% of the B. fragilis strains and 10.4% of all Bactero-
ides/Parabacteroides isolates were resistant to amoxicillin/cla-
vulanic acid, with no differences in the CLSI and EUCAST
resistance breakpoints. For all non-fragilis isolates, the
resistance rates to this antibiotic were higher than those
for the B. fragilis isolates, in the range 11.5% and 30%.
Among all the isolates tested, a ten-fold higher resistance
rate was found in Europe relative to the ﬁrst study
(Tables 2 and 3).
Piperacillin/tazobactam
Major differences in resistance rates were observed when
the CLSI or EUCAST breakpoints were used to evaluate the
MIC results for piperacillin/tazobactam: 3.1% vs. 10.3% for all
isolates tested, and 1.7% vs. 6.5% for B. fragilis, respectively.
All non-fragilis species displayed much higher resistance rates
than all B. fragilis isolates according to both breakpoints. Dur-
ing the second study, only <1% of the strains were resistant,
in comparison with 3.1% in the present study, according to
the CLSI breakpoints (Tables 2 and 3).
Cefoxitin
Only CLSI breakpoints are available for cefoxitin: 17.2% of all
isolates and 13.7% of the B. fragilis strains proved resistant.
The resistance rates were highest among Parabacteroides
distasonis (35.7%), B. thetaiotaomicron (27.1%) and B. ovatus
(24.5%). The less frequent Bacteroides species also displayed a
high resistance rate (26.9%). Comparison of the results of
the three studies reveals a very signiﬁcant increase in overall
resistance rate to cefoxitin among Bacteroides strains during
the past 20 years (3%, 6% and 17.2%, respectively) (Table 3).
Imipenem
Fewer than 1% of all isolates and 1.2% of the B. fragilis iso-
lates were resistant to imipenem. The CLSI and EUCAST
resistance breakpoints did not differ. Altogether, seven B. fra-
gilis isolates from ﬁve countries (Finland, France, Hungary,
the Netherlands and Turkey) were resistant, with MICs
‡16 mg/L (Table 4). The level of imipenem resistance has
not changed dramatically during the past 20 years (0%, <1%
and 1.2%), although the percentage of isolates with reduced
susceptibilities (MIC: ‡4 mg/L) has increased steadily (0.3%,
1.6% and 2.7%) (Tables 2 and 3). The 22 strains with MIC
‡4 mg/L originated from ten countries, distributed equally
in the different regions, with most isolated from abscesses/
wounds (11) intraabdominal samples (4) and blood (3)
(Table 4). Resistance to other drugs was observed in all
strains and 11 isolates were resistant to more than two
other drugs. All strains were susceptible to metronidazole
TABLE 1. Distribution of Bacteroides/Parabacteroides strains according to isolation source
Isolation source (number of isolates)
Number of isolates
OthersBFR BTH BOV BVU PDI BUN PME BEG BCA
Abdominal infections (except appendicitis) (258) 185 18 19 16 3 1 2 1 1 1 Bacteroides stercoris
1 Bacteroides nordii
1 Bacteroides spp.
Wounds (99) 86 6 1 3 1 1 1 Bacteroides massiliensis
Diabetic foot infections (77) 61 9 3 1 2 1
Blood (76) 49 16 2 5 1 1 2 B. nordii
Abscesses (55) 32 8 2 4 2 2 1 1 1 Bacteroides salyersae
1 B. massiliensis
1 Bacteroides intestinalis
Ulcers, skin infections, decubitus (54) 33 8 3 3 4 1 1 1
Male/female genital infections (46) 30 4 4 5 2 1 B. nordii
Rectal, anal, perirectal abscesses (38) 28 3 3 2 1 1
Appendicitis (38) 27 4 2 3 1 B. massiliensis
1 Parabacteroides goldsteinii
Ear and nose (36) 26 4 3 1 1 1
Respiratory tract (11) 7 1 1 1 1
Others (37) 36 8 1
Total (824) 600 83 49 42 14 10 7 5 2 12
Percentage (100) 72.8 10.0 6.0 5.1 1.7 1.2 <1 <1 <1 1.5
BFR, Bacteroides fragilis; BTH, Bacteroides thetaiotaomicron; BVU, Bacteroides vulgatus; BOV, Bacteroides ovatus; PDI, Parabacteroides distasonis; BUN, Bacteroides uniformis; BCA,
Bacteroides caccae; PME, Parabacteroides merdae; BEG, Bacteroides eggerthi.
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TABLE 2. In vitro activities of nine antibiotics against 824 Bacteroides/Parabacteroides strains
Number of strains
MIC (mg/L)
Resistance % at
breakpoints (mg/L)
Range MIC50 MIC90 CLSI EUCAST
Ampicillin ‡2 >2
Bacteroides fragilis group 824 1–>256 32 >256 99.2 98.2
B. fragilis 600 1–>256 32 >256 99.0 97.4
Bacteroides thetaiotaomicron 83 2–>256 64 >256 100 98.8
Bacteroides ovatus 49 8–>256 64 >256 100 100
Bacteroides vulgatus 42 4–>256 64 >256 100 100
Parabacteroides distasonis 14 8–>256 16 >256 100 100
Bacteroides uniformis 10 16–>256 32 >256 100 100
Other species 26 4–>256 64 >256 100 100
Amoxicillin/clavulanic acid ‡16 >8
B. fragilis group 824 0.016–>256 1 16 10.4
B. fragilis 600 0.016–>256 1 16 8.7
B. thetaiotaomicron 83 0.125–32 1 16 12.0
B. ovatus 49 0.25–32 1 16 18.4
B. vulgatus 42 0.125–256 1 16 14.3
P. distasonis 14 0.5–256 2 32 21.4
B. uniformis 10 0.125–64 1 64 30.0
Other species 26 0.125–64 2 16 11.5
Piperacillin/tazobactam ‡128 >16
B. fragilis group 824 0.016–>256 4 32 3.1 10.3
B. fragilis 600 0.016–>256 2 16 1.7 6.5
B. thetaiotaomicron 83 0.125–>256 16 128 12.0 32.5
B. ovatus 49 0.25–32 8 32 0 14.2
B. vulgatus 42 0.25–256 8 32 4.8 14.3
P. distasonis 14 2–256 8 64 14.3 21.4
B. uniformis 10 0.5–256 4 16 10.0 10.0
Other species 26 0.125–64 8 16 15.4 46.1
Cefoxitin ‡64 –
B. fragilis group 824 1–>256 16 128 17.2 –
B. fragilis 600 1–>256 16 256 13.7 –
B. thetaiotaomicron 83 2–>256 32 256 27.1 –
B. ovatus 49 1–256 32 256 24.5 –
B. vulgatus 42 1–>256 8 64 14.3 –
P. distasonis 14 8–>256 32 >256 35.7 –
B. uniformis 10 2–256 8 256 20.0 –
Other species 26 2–>256 16 >256 26.9 –
Imipenem ‡16 >8
B. fragilis group 824 0.002–>32 0.5 1 0.85
B. fragilis 600 0.002–>32 0.25 0.5 1.2
B. thetaiotaomicron 83 0.047–8 0.25 1 0
B. ovatus 49 0.016–2 0.25 1 0
B. vulgatus 42 <0.125–2 0.125 0.5 0
P. distasonis 14 0.125–2 0.5 1 0
B. uniformis 10 0.125–2 0.125 1 0
Other species 26 0.012–8 0.5 4 0
Clindamycin ‡8 >4
B. fragilis group 824 0.016–>256 2 >256 32.4
B. fragilis 600 0.016–>256 1 256 28.5
B. thetaiotaomicron 83 0.047–>256 4 >256 42.2
B. ovatus 49 0.125–>256 4 >256 44.9
B. vulgatus 42 0.016–>256 2 >256 47.6
P. distasonis 14 0.016–>256 1 >256 28.6
B. uniformis 10 1–256 8 256 60.0
Other species 26 0.047–256 2 256 34.6
Moxifoxacin ‡8 –
B. fragilis group 824 <0.125–32 1 16 13.6 –
B. fragilis 600 <0.125–64 0.5 8 14.0 –
B. thetaiotaomicron 83 0.125–32 1 16 14.5 –
B. ovatus 49 <0.125–32 1 4 8.2 –
B. vulgatus 42 <0.125–64 1 32 21.4 –
P. distasonis 14 <0.125–2 0.5 1 0 –
B. uniformis 10 <0.125–4 1 4 0 –
Other species 26 <0.125–32 0.25 4 11.5 –
Metronidazole ‡32 >4
B. fragilis group 824 0.016–256 0.5 1 0.25 0.5
B. fragilis 600 0.016–32 0.5 1 0.2 0.5
B. thetaiotaomicron 83 <0.125–>256 0.5 2 1.2 1.2
B. ovatus 49 0.032–2 0.5 2 0 0
B. vulgatus 42 <0.125–4 0.5 1 0 0
P. distasonis 14 0.125–2 0.5 1 0 0
B. uniformis 10 0.016–2 0.5 1 0 0
Other species 26 <0.125–4 0.5 2 0 0
Tigecycline ‡16 –
Bacteroides fragilis group 824 0.016–32 0.25 2 1.7 –
B. fragilis 600 0.016–32 0.5 2 1.8 –
B. thetaiotaomicron 83 0.06–8 0.25 0.5 0 –
B. ovatus 49 0.032–16 0.25 2 2.0 –
B. vulgatus 42 <0.125–16 2 4 4.8 –
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and tigecycline. Only one strain showed resistance to pipe-
racilin/tazobactam according to the CLSI breakpoint, whereas
12 were resistant according to the EUCAST breakpoint.
Table 5 shows the in vitro activities of the different antibiotics
tested against the 22 imipenem-nonsusceptible strains taking
into consideration the EUCAST susceptibility breakpoint
TABLE 2. (Continued)
Number of strains
MIC (mg/L)
Resistance % at
breakpoints (mg/L)
Range MIC50 MIC90 CLSI EUCAST
P. distasonis 14 0.125–4 0.5 2 0 –
B. uniformis 10 0.016–16 0.125 1 10 –
Other species 26 0.047–8 0.25 1 0 –
EUCAST, European Committee on Antimicrobial Susceptibility Testing.
TABLE 3. Resistance rates of Bacteroides strains in three Europe-wide studies according to the CLSI breakpoints
Antibiotics
Resistance breakpoints
(mg/L)
Resistance (%) in
First study [10]: No. 1289 Second study [11]: No. 1284 Present study: No. 824
Ampicillin ‡2 93 99.3 99.2
High-level resistance ‡64 16 27 44.5
Amoxicillin/clavulanic acid ‡16 1 – 10.4
Piperacillin/tazobactam ‡128 – <1 3.1
Cefoxitin ‡64 3 6 17.2
Imipenem ‡16 0 <1 1.2
reduced susceptibility ‡4 0.3 1.6 2.7
Clindamycin ‡8 9 15 32.4
Moxiﬂoxacin ‡8 – 9 13.6
Metronidazole ‡32 0 <1 <1
reduced susceptibility ‡4 0.1 3.3 2.7
Tigecycline ‡16 – – 1.7
TABLE 4. Antibiotic susceptibilities of Bacteroides/Parabacteroides isolates with reduced susceptibility to imipenem (MIC: 4–
>32 mg/L)
Country Strain/source
MIC (mg/L)
AMP AMOX/CLAV PIP/TAZO CFX IMI CLIN MOXI MTZ TIGE
Sweden 42 Bacteroides fragilis/bl 32 8 16 16 4 1 <0.125 0.25 0.5
Sweden 46 B. fragilis/wd >256 16 2 256 4 2 16 1 1
Sweden 83 B. fragilis/bl 8 4 32 32 4 0.5 0.25 0.25 0.5
Finland 63 B. fragilis/wd >256 4 4 >256 4 0.25 0.5 0.5 1
Finland 37 B. fragilis/as >256 0.5 >256 >256 >32 >256 0.5 1 1
Finland 87 B. fragilis/wd >256 64 32 >256 >32 8 0.25 1 0.25
The Netherlands H3 B. fragilis/ab >256 >32 >32 64 >32 0.25 4 0.5 0.125
Belgium M28 Bacteroides thetaiotaomicron/un >256 16 64 64 4 0.5 0.5 0.125 <0.125
Belgium A22 B. thetaiotaomicron/un >256 32 >32 64 8 2 32 2 2
Germany 14 B. fragilis/gf 1 1 <0.125 64 4 <0.125 0.125 2 0.125
Italy 15 B. fragilis/ab 16 16 32 64 4 1 4 0.25 0.25
Turkey 38 B. fragilis/as 4 1 2 >256 4 4 1 1 0.25
Turkey 27 B. fragilis/as 64 32 64 64 16 0.125 <0.125 0.25 <0.125
Turkey 31 B. fragilis/as 32 16 64 32 16 0.125 <0.125 0.25 <0.125
Greece 67 Bacteroides eggerthii/bl >256 >32 64 64 4 >32 16 <0.125 <0.125
Greece 70 Parabacteroides merdae/as 4 2 32 32 4 8 0.25 0.25 0.5
France 9 B. fragilis/wd 8 4 4 256 32 0.125 0.25 16 0.125
Hungary 25 B. fragilis/ab >256 >256 32 256 4 256 >32 2 2
Hungary 51 B. fragilis/rs 64 0.5 1,5 32 4 2 0.25 2 2
Hungary 92 B. fragilis/as 32 4 8 >256 8 8 0.25 1 1
Hungary 59 Bacteroides stercoris/ab 64 8 16 16 8 <0.125 0.125 2 <0.125
Hungary 61 B. fragilis/wd 256 0.5 2 4 32 8 0.125 1 0.25
ab, abdominal; as, abscess; bl, blood sample; gf, genital, female; rs, respiratory tract specimen; un, unknown; wd, wound.
Bold: resistant according to the CLSI breakpoints (15).
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(imipenem MIC: ‡4 mg/L). For all antibiotics except tigecy-
cline, where no resistant or intermediate-resistant strain was
found among the imipenem-nonsusceptible isolates, and clin-
damycin, where the resistance rate was almost the same
among imipenem-nonsusceptible and all isolates, the resis-
tance rates were signiﬁcantly higher among the isolates
which were nonsusceptible to imipenem (Table 5).
Clindamycin
After ampicillin, the highest resistance rates were found to
clindamycin: 28.5–60% for the different species, with no dif-
ferences in the CLSI and EUCAST breakpoints. The resis-
tance was 32.4% for all isolates and 28.5% for the B. fragilis
isolates (Table 2). Bacteroides uniformis and B. vulgatus were
most resistant. Clindamycin demonstrated the most dramatic
changes in the three studies: resistance of 9%, 15% and
32.4% for all isolates, respectively (Table 3). In the ﬁrst
study, B. thetaiotaomicron (13%) and B. uniformis (13%); in the
second, B. vulgatus (30%) and B. ovatus (25%); and, in the
third study, B. uniformis (60%) and B. vulgatus (47.6%) were
the most resistant species.
Moxiﬂoxacin
The EUCAST system gives no resistance breakpoint for
moxiﬂoxacin. With the CLSI breakpoint (‡8 mg/L), 13.6% of
all isolates and 14% of B. fragilis showed resistance to moxi-
ﬂoxacin. In the ﬁrst study, ciproﬂoxacin was tested with very
high resistance rates at the breakpoint ‡4 mg/L (37–98%
according to the different species). Compared to the second
study, the overall resistance rate to moxiﬂoxacin increased
from 9% to 13.6%. In both studies, the most resistant species
was B. vulgatus, with resistance rates of 19% and 21.4%,
respectively.
Metronidazole
The vast majority of the Bacteroides/Parabacteroides species
were susceptible, with the CLSI (‡32 mg/L) and the EUCAST
resistance breakpoint (>4 mg/L) both showing <1% resis-
tance for all isolates. One B. thetaiotaomicron (MIC >256 mg/
L) isolated from blood culture and one B. fragilis (MIC:
32 mg/L) from an abscess proved resistant according to the
CLSI breakpoint. Two further B. fragilis isolates (MICs: 8 and
16 mg/L), both from postsurgical wounds, were resistant
when the EUCAST breakpoint was used. These were iso-
lated in Croatia, Finland, France and Hungary. No signiﬁcant
difference in resistance was observed during the three
Europe-wide studies (0%, <1% and <1% resistance). On eval-
uation of isolates with MICs ‡4 mg/L, in the present study,
22 of 824 strains (2.7%) belonged to this group; they were
obtained from six countries, with between one and nine iso-
lates per country. In the previous study, 43 of 1284 isolates
(3.3%) from 14 countries had MICs ‡4 mg/L and were
regarded as strains exhibiting reduced susceptibility
(Table 6). The ﬁrst study revealed only one isolate of 1289
(0.1%), with reduced susceptibility. Only six of the 22 iso-
lates exhibited resistance to more than two other antibiotics.
All isolates with reduced susceptibility to metronidazole
were susceptible to tigecycline and, except one, to imipenem
(Table 6). Similarly, as previously noted, where one strain
proved resistant to both metronidazole and imipenem, the
present study detected only one strain with resistance to im-
ipenem (MIC 32 mg/L), with MIC 16 mg/L for metronidazole
(resistant according to the EUCAST breakpoint).
Tigecycline
This is the ﬁrst member of a new family of antimicrobial
agents, the glycylcyclines, derived from a tetracycline
nucleus, but not affected by existing tetracycline-resistance
mechanisms. Because no resistance breakpoint is yet
accepted by EUCAST, the CLSI breakpoint was used for
evaluation. Only 1.7% among all isolates proved resistant,
whereas 1.8% of the B. fragilis strains showed resistance.
B. vulgatus and B. ovatus had the highest resistances: 4.8%
and 2.0%, respectively.
TABLE 5. In vitro activities of antimicrobials against 22 Bacteroides strains with reduced susceptibilities to imipenem (MIC
‡4 mg/L)
Drug Breakpoints (S/R)a MIC range mg/L MIC50 mg/L MIC90 mg/L %S %I %R %R of all strains
Ampicillin 0.5/>2 1–>256 64 >256 0 4.6 95.4 98.2
Amoxillin/clavulanic acid £4/>8 0.5–>256 8 64 45.5 9.1 43.4 10.4
Piperacillin/tazobactam £8/>16 0.125–>256 32 64 36.4 4.5 59.1 10.3
Cefoxitin £16/‡64 4–>256 64 >256 13.6 27.3 59.1 17.2
Imipenem £2/>8 4–>32 4 >32 0 68.2 31.8 0.8
Clindamycin £4/>4 <0.125–>256 1 64 68.2 0 31.8 32.4
Metronidazole £4/>4 <0.125–16 1 2 95.5 0 4.5 0.5
Moxiﬂoxacin £2/‡8 <0.125–>32 0.25 16 72.8 9.1 18.1 13.6
Tigecycline £4/‡16 <0.125–2 0.25 2 100 0 0 1.7
aBreakpoints are deﬁned by the European Committee on Antimicrobial Susceptibility Testing where available; cefoxitin, moxiﬂoxacin and tigecyclin breakpoints deﬁned by the
CLSI.
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National and inter-regional differences in resistance rates
The participating countries were grouped into four different
regions: the Scandinavian countries: Finland (FIN) and
Sweden (SWE); the Northern continental countries: the
Netherlands (NETH), Belgium (BELG) and Germany (GER);
the Mediterranean countries: Spain (ESP), France (FRA),
Greece (GRC), Italy (ITA) and Turkey (TRK); and the east-
ern countries: Croatia (CRO), Czech Republic (CZE) and
Hungary (HUN). Data for Spain were not evaluated when
resistance rates were compared by countries. Despite the
differences between the numbers of strains submitted by dif-
ferent countries, the numbers of strains investigated were
approximately similar in the four geographical areas
(between 182 and 248) (Table 7). No differences between
countries or regions were observed in the resistance to
ampicillin. The resistance to amoxicillin/clavulanic acid varied
TABLE 6. Antibiotic susceptibilities of Bacteroides isolates with reduced susceptibilities to metronidazole (MIC: 4–256 mg/L)
Country Strain/source
MIC (mg/L)
AMP AMOX/CLAV PIP/TAZO CFX IMI CLIN MOXI MTZ TIGE
Finland 1 Bacteroides fragilis/ux >256 1 0.5 8 1 1 0.5 4 0.06
Finland 17 B. fragilis/ab >256 2 0.125 4 0.125 0.25 0.25 4 0.125
Finland 46 B. fragilis/aw >256 4 1 4 0.5 1 2 4 0.25
Finland 57 B. fragilis/ab >256 0.5 2 64 0.06 >256 1 32 0.125
Germany 13 B. fragilis/wd 32 2 1 32 0.5 2 >32 4 1
Germany 25 B. fragilis/rs 2 2 4 16 0.125 4 0.25 4 1
Germany 37 B. fragilis/ab 256 2 256 >256 0.125 4 2 4 0.5
Belgium M16 B. fragilis/bl 64 4 4 8 0.25 >256 8 4 1
France 9 B. fragilis/wd 8 4 4 256 32 0.125 0.25 16 0.125
France 4 B. fragilis/ab 32 1 0.25 256 0.125 1 0.25 4 0.25
France 6 B. fragilis/re >256 8 2 8 0.25 0.25 0.5 4 0.25
France 22 Bacteroides thetaiotaomicron/as 32 1 0.25 2 0.25 0.25 0.5 4 0.125
Hungary 22 B. fragilis/ab 128 2 8 256 0.5 8 >32 4 2
Hungary 23 B. fragilis/gf >256 32 64 256 0.5 16 2 4 0.5
Hungary 29 B. fragilis/as 64 0.125 4 16 0.25 4 1 4 0.25
Hungary 31 B. fragilis/ab 32 0.125 2 16 0.25 1.5 0.25 4 1
Hungary 41 B. fragilis/ab 32 0.125 4 8 0.25 1 0.25 4 0.5
Hungary 32 B. fragilis/ab 16 1 16 8 0.5 4 0.25 4 1
Hungary 38 Bacteroides stercoris/ab 32 0.125 0.25 32 <0.125 1 0.125 4 0.25
Hungary 14 Bacteroides vulgatus/gf 32 1 4 16 0.25 0.06 4 4 8
Hungary 66 B. thetaiotaomicron/bl 16 2 0.06 2 0.06 16 0.5 256 0.125
Croatia 4 B. fragilis/wd 8 0.5 1 4 <0.125 64 0.5 8 0.5
ab, abdominal; as, abscess; aw, anal wound; bl, blood sample; gf, genital, female; rs, respiratory tract specimen; wd, wound.
Bold indicates resistance according to CLSI breakpoints (15).
TABLE 7. Antibiotic resistance rates among all isolates according to countries and regions
Country/Region
Number of
isolates
Percentage (%) of isolates resistant to
AMP AMOX/CLAV PIP/TAZ FOX IMI CLIN MOXI MTZ TIGE
Breakpointsa >2 >8 >16 ‡64 >8 >4 ‡8 >4 ‡16
FIN 85 100 5.9 12.9 30.6 2.4 23.5 12.9 1.2 1.2
SWE 97 100 11.3 19.6 21.7 0 21.7 28.9 0 0
Scandinavian 182 100 8.8 16.5 25.8 1.1 22.5 21.4 0.6 0.6
NETH 32 100 3.1 3.1 3.1 3.1 21.9 6.2 0 0
BELG 103 97.1 18.5 9.7 6.8 0 26.2 17.5 0 2.9
GER 72 88.9 2.8 7.0 27.8 0 19.5 16.7 0 4.2
Northern continental 207 94.2 10.6 8.7 13.5 0.5 23.2 15.5 0 2.4
ESP 3 66.6 33.3 33.3 33.3 0 0 33.3 0 0
FRA 51 100 2.0 3.9 19.9 2.0 31.4 3.9 2.0 0
GRC 75 98.7 17.3 13.3 16.0 0 50.7 6.7 0 2.7
ITA 23 95.6 8.7 17.4 8.7 0 21.7 0 0 4.3
TRK 34 100 17.6 8.8 14.7 5.8 52.9 8.8 0 0
Mediterranean 186 96.8 12.4 11.8 16.2 1.6 41.9 5.4 0.5 1.6
CRO 56 98.2 8.8 3.5 5.3 0 44.6 7.0 1.8 0
CZE 91 100 3.3 6.9 8.9 0 17.6 13.2 0 1.1
HUN 100 100 15 12 24 1 27 12 1 2
Eastern 248 99.6 9.3 8.1 14.1 0.4 29.7 11.3 0.8 1.2
AMP, ampicillin; AMOX/CLAV, amoxicillin/clavulanic acid; PIP/TAZ, piperacillin/tazobactam; FOX, cefoxitin; IMI, imipenem; CLIN, clindamycin; MOXI, moxiﬂoxacin; MTZ,
metronidazole; TIGE, tigecycline.
aResistance breakpoints of the European Committee on Antimicrobial Susceptibility Testing were used, except for FOX, MOXI and TIGE, where only CLSI breakpoints are
available.
Bold indicates average numbers for regions.
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from 2% in France to 18.5% in Belgium, and that to piperacil-
lin/tazobactam from 3.1% in the Netherlands to 19.6% in
Sweden. Cefoxitin resistance varied markedly, with the low-
est resistance rate in the Netherlands (3.1%) and the highest
in Finland (30.6%). Apart from the Czech Republic (17.6%)
and Germany (19.5%), clindamycin resistance was higher than
20%, and highest in Greece (50.7%) and Turkey (52.9%). The
most expressed differences in the regional data were
observed in the case of clindamycin, where the highest resis-
tance was found in the Mediterranean countries (41.9%) fol-
lowed by the eastern countries (29.7%) and lower resistance
rates in the two other regions (22.5 and 23.2%). Moxiﬂoxa-
cin resistance varied considerably: in Italy, no resistant strains
were found, whereas the resistance rate in Sweden was
28.9%. Regional differences were remarkable, being as high
as 21.4% in the Scandinavian countries and 5.4% in Mediter-
ranean region. Low resistances were found for imipenem,
metronidazole and tigecycline in all regions, although the
tigecycline resistance exceeded 4% in Germany and Italy.
Discussion
Although Bacteroides spp. may cause severe infections, the
treatment seldom is guided by susceptibility testing results,
mostly because of the availability of broad-spectrum antibiot-
ics covering aerobic and anaerobic bacteria in mixed infec-
tions. The isolation and identiﬁcation of anaerobic bacteria,
followed by antibiotic susceptibility testing, are time-consum-
ing procedures; the cost and complexity of the testing and
the assumption that susceptibility patterns among anaerobes
are predictable therefore lead to ever less frequent routine
testing of these pathogens in different countries. However,
species determination of Bacteroides strains may be important
because signiﬁcant differences in resistance rates to various
antibiotics can be observed among different species [9–11].
Few countries in Europe carry out regular resistance surveil-
lance on anaerobic bacteria on a reasonable number of fresh
clinical isolates aiming to follow resistance development [3–
6]. In Spain, considerable increases in resistance rates to
cefoxitin (12.8% vs. 27.1%), clindamycin (33.5% vs. 47.9%),
moxiﬂoxacin (6% vs. 25%) and amoxicillin/clavulanic acid (5%
vs. 17.9%) were observed in a 10-year period [6]. The ten-
dencies were similar in France for clindamycin [7] and in Bel-
gium for amoxicillin/clavulanic acid and clindamycin [3]. The
recent multicentre study by Snydman et al. [9] involving 5225
Bacteroides isolates from ten medical centres in the USA,
reviewed resistance development between 1997 and 2004.
They found very low resistance rates to piperacallin/
tazobactam over the 8 years (0.5% for all isolates), whereas
our recent study revealed a resistance rate of 3.1% for all
isolates, with an increase during the past 10 years, but a
much higher resistance for P. distasonis (14.3%). With the
same breakpoints, the highest resistance rate to cefoxitin
was found for P. distasonis both in the present study and in
the US survey (35.7% and 29.9%, respectively). No dramatic
changes in imipenem and metronidazole resistance were
demonstrated over the year, although the numbers of
strains with reduced susceptibilities to these drugs are sel-
dom evaluated. Among these strains, increased resistance
rates to other drugs were clearly seen in both the second
ESGARAB study and the present study [11]. Tigecycline
proved highly active in the present study (1.7% resistance)
and during the last 5 years according to the US study (4.3%
overall resistance) [9]. The results of the three Europe-
wide studies over the 20 years revealed geographical differ-
ences in resistance rates to one or more anti-anaerobic
drugs, probably because of differences in general antibiotic
usage in different countries [10,11]. Further studies are
required to identify resistance genes in imipenem and met-
ronidazole-nonsusceptible strains in Europe. Rapid and
reliable species determination and continuing surveillance
of the resistance development in Bacteroides strains are
essential.
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